Masitinib is an oral treatment designed to block the activity of multiple cell types — including macrophages, neutrophils, mast cells, and Schwann cells — involved in the inflammatory and neurodegenerative processes marking ALS. It does so through the activity of proteins called tyrosine kinases.1

Check AB Science page to know more.


The titles of the articles are clickable and will redirect you to the online resource. The quote is the conclusion or an extract of the article. Please be sure to read them fully

2019 - Add-on Masitinib Slows Progression of ALS, Final Phase 2/3 Trial Results Show

Download PDF

Masitinib in combination with Rilutek (riluzole) slows functional decline of patients with amyotrophic lateral sclerosis (ALS) who have a typical disease progression, according to the final report of AB Science‘s Phase 2/3 clinical trial.

At 11 months of treatment with the combo, the rate of disability progression was reduced by 27%, as compared to a placebo plus Rilutek. In contrast, patients who have a faster disease worsening do not benefit as much from adding masitinib to their treatment.

PhaseII results

  1. from ALS News Today ↩︎